Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that the first commercial case has ...
Read full article: Low off the coast brings in drier changes for Central Florida ORLANDO, Fla. – A bill currently making its way through the Florida Legislature is aimed at limiting opioid ...
SYDNEY, May 26, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced ...
Superior, Non-Opioid Therapy Now Delivered in a Smaller and More Refined IPG REDWOOD CITY, California, Nov. 30, 2017 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is ...
REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, ...
Nevro Corp. has won pre-market approval from the Food and Drug Administration for its Senza spinal cord stimulation device. The Redwood City, California-based company previously got an FDA nod in May ...
A third-quarter earnings report that beat expectations lifted spirits and the medical-device stock. After the bell on Wednesday, Nevro told investors that third-quarter revenue reached $100.2 million, ...
Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge. The optimism led by a solid third-quarter 2022 performance and continued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback